CRF to provide groundbreaking clinical trial findings at TCT 2013 scientific symposium The Cardiovascular Research Foundation has announced the late breaking trials and first report investigations that’ll be presented at next month's Transcatheter Cardiovascular Therapeutics 2013 scientific symposium. TCT, the world's premier educational meeting focusing on interventional cardiovascular medicine, will take place October 28 – November 1, 2013 at The Moscone Middle in San Francisco, California. Clinical trial data and first record investigations provided at TCT often direct the course of patient therapies ed medications . The studies selected will shed new light on the performance and safety of minimally invasive methods, pharmaceuticals, technologies and gadgets that show potential to take care of or prevent coronary disease, among the leading factors behind death globally.

We will focus on targets which affect the primarily pro-tumour role of myeloid cells in solid malignancies, an area in which my lab is rolling out significant experience. We’d anticipate such therapies to be relevant across a variety of tumour types. Among our first regions of interest shall be in the biology of myeloid cells in cancer, which has been an certain region of focus for us for many years. Dr Phil L’Huillier, CRT’s director of business advancement, said: CRT has a strong interest in exploring the exciting section of the tumour microenvironment to create innovative new cancer therapies. Tumour connected macrophages are recognised as important players progressively in cancer, and combining BioInvent’s unique antibody discovery platform with Dr Hagemann’s knowledge in the macrophage field provides this collaboration with a unique blend of skills to develop multiple therapeutic tasks with the potential to advantage cancer patients ..